Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Jun Pyo Kim *Center for Neuroimaging, Radiology and Imaging Sciences, and the Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, 340 West 10th St, Indianapolis, IN 46202, USA.ORCID http://orcid.org/0000-0003-4376-3107
Kwangsik Nho *Center for Neuroimaging, Radiology and Imaging Sciences, and the Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, 340 West 10th St, Indianapolis, IN 46202, USA.ORCID http://orcid.org/0000-0002-7624-3872
Tingting WangBaker Heart and Diabetes Institute, 75 Commercial Rd, Melbourne, VIC, 3004, Australia.
Shannon L RisacherCenter for Neuroimaging, Radiology and Imaging Sciences, and the Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, 340 West 10th St, Indianapolis, IN 46202, USA.ORCID http://orcid.org/0000-0002-3304-7943
Paula J BiceCenter for Neuroimaging, Radiology and Imaging Sciences, and the Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, 340 West 10th St, Indianapolis, IN 46202, USA.
Bruce S KristalDivision of Sleep and Circadian Disorders, Department of Medicine, Brigham and Women's Hospital, and Division of Sleep Medicine, Harvard Medical School, 25 Shattuck St, Boston, MA, 02115, US.ORCID http://orcid.org/0000-0001-6103-7745
Colette BlachDuke Molecular Physiology Institute, Duke University, Durham, NC, 27708, USA.
Rebecca BaillieRosa & Co LLC, 751 Laurel St. Ste. 127, San Carlos, California, 94070, USA.
Gabi KastenmüllerInstitute of Computational Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764, Neuherberg, Germany.
Andrew J SaykinCenter for Neuroimaging, Radiology and Imaging Sciences, and the Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, 340 West 10th St, Indianapolis, IN 46202, USA. asaykin@iu.edu.ORCID http://orcid.org/0000-0002-1376-8532
Rima Kaddurah-DaoukDepartment of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, 27708, USA. rima.kaddurahdaouk@duke.edu.ORCID http://orcid.org/0000-0003-1858-5732
Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI Paul S. Aisen · 2016 to 2026
$226.7M
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Project 4 - Mechanistic studies on the role of the gut microbiome in models for Alzheimer's diseaseU19AG063744 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ROB KNIGHT, Rima F Kaddurah-Daouk · 2019 to 2026
$54.1M
Peripheral and Central Biomarkers of Alzheimer's Disease in Diverse CohortsU19AG074879 · NIA · MAYO CLINIC JACKSONVILLE · PI Minerva Maria Carrasquillo, NILUFER ERTEKIN-TANER · 2023 to 2026
$42.0M
Research Education ComponentP30AG072976 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI ANDREW J SAYKIN · 2021 to 2026
$24.1M
Ultrascale Machine Learning to Empower Discovery in Alzheimers Disease BiobanksU01AG068057 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Christos Davatzikos, Heng Huang · 2020 to 2026
$20.7M
KBASE2: Korean Brain Aging Study, Longitudinal Endophenotypes and Systems BiologyU01AG072177 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI LEE, DONG YOUNG, NHO, KWANGSIK TIMOTHY · 2021 to 2025
$11.2M
Metabolomic Signatures for Disease Sub-classification and Target Prioritization in AMP-ADU01AG061359 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KASTENMULLER, GABI · 2018 to 2022
$10.0M
Metabolic Signatures Underlying Vascular Risk Factors for Alzheimer-type DementiasRF1AG051550 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KLING, MITCHEL ALLAN · 2015 to 2016
$6.3M
Metabolic Networks and Pathways Predictive of Sex Differences in AD Risk and Responsiveness to TreatmentRF1AG059093 · NIA · DUKE UNIVERSITY · PI BRINTON, ROBERTA EILEEN, CHANG, RUI · 2018 to 2018
$5.9M
Metabolic Network Analysis of Biochemical Trajectories in Alzheimer's DiseaseRF1AG057452 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KASTENMULLER, GABI · 2017 to 2017
$3.5M
Gut Liver Brain Biochemical Axis in Alzheimer's DiseaseRF1AG058942 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, VAN DUIJN, CORNELIA MARJA · 2018 to 2018
$3.4M
Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) DAOU16AMPANIA NIH HHS P30 AG072976NIA NIH HHS RF1 AG051550NIA NIH HHS RF1 AG057452NIA NIH HHS RF1 AG058942NIA NIH HHS RF1 AG059093NIA NIH HHS U01 AG024904NIA NIH HHS U01 AG061359NIA NIH HHS U01 AG068057NIA NIH HHS U01 AG072177NIA NIH HHS U19 AG024904NIA NIH HHS U19 AG063744NIA NIH HHS U19 AG074879U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01AG059093U.S. Department of Health & Human Services | National Institutes of Health (NIH) RF1AG051550U.S. Department of Health & Human Services | National Institutes of Health (NIH) RF1AG057452U.S. Department of Health & Human Services | National Institutes of Health (NIH) RF1AG058942U.S. Department of Health & Human Services | National Institutes of Health (NIH) U01AG061359U.S. Department of Health & Human Services | National Institutes of Health (NIH) U19AG063744
6 · The paper itself
Abstract
Investigating the relationship of circulating lipidome profiles with cross-sectional and longitudinal changes of central Alzheimer's disease (AD) biomarkers, including amyloid/tau/neurodegeneration (A/T/N), can provide a holistic view between the lipidome and AD pathophysiology. In this study, we quantified a total of 749 plasma lipid species at baseline using liquid chromatography-mass spectrometry and performed cross-sectional and longitudinal association analysis of plasma lipidome profiles with longitudinal A/T/N biomarkers for AD in the Alzheimer's Disease Neuroimaging Initiative cohort (N = 1395). We identified several lipid species, classes, and network modules of correlated lipids that were significantly associated with cross-sectional and longitudinal changes of A/T/N biomarkers. Notably, we identified lysoalkylphosphatidylcholine (LPC(O)) as associated with cross-sectional "A/N" biomarkers at the lipid species, class, and module levels. Also, Phosphatidylethanolamine (PE) ethers were associated with A/T/N biomarkers in the species level and with "N" biomarkers in the class and module levels. G
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Circulating lipids are related to longitudinal changes of ATN biomarkers for Alzheimer's disease. · full record | OpenQuestion